Company Overview of MicroBiome Therapeutics, LLC
MicroBiome Therapeutics, LLC, a biotechnology company, develops medical food and pharmaceutical products. The company focuses on developing evidence-based microbiome modulators, which are designed to alter bacteria populations and their environment in the gastrointestinal tract in specific ways to treat and prevent serious health conditions. Its product includes NM504, which contains a combination of prebiotic and other naturally occurring ingredients formulated to help diabetic individuals achieve healthy blood glucose levels and manage their body weight. MicroBiome Therapeutics, LLC was formerly known as NuMe Health LLC. The company was founded in 2009 and is based in Broomfield, Colorado.
11001 W 120th Avenue
Broomfield, CO 80021
Founded in 2009
Key Executives for MicroBiome Therapeutics, LLC
Chief Scientific Officer and Vice President of Research
Compensation as of Fiscal Year 2015.
MicroBiome Therapeutics, LLC Key Developments
MicroBiome Therapeutics Receives Positive Response from FDA for Use of Expedited Regulatory Pathway for Diabetes Drug NM505
May 12 15
MicroBiome Therapeutics LLC reported that the U.S. Food & Drug Administration (FDA) has responded positively to the company's pre-IND request to use the 505(b)(2) abbreviated regulatory pathway for development of lead product NM505. This pathway allows the use of existing safety and efficacy data on the drug's key active ingredient along with relevant data in the public domain to reduce the size, scope, timeline and cost of the clinical program required for FDA submission and review.
Steve Orndorff to Resign as CEO of MicroBiome Therapeutics LLC at the End of May 2015
May 12 15
MicroBiome Therapeutics LLC announced that CEO Steve Orndorff will be resigning at the end of May 2015 to head up a new biopharmaceutical venture close to his home.
MicroBiome Therapeutics Receives Notice Of Allowance For U.S. Patent Covering Glyceollin As a Treatment For Diabetes And Obesity
Feb 9 15
MicroBiome TherapeuticsTM LLC (MBT) reported that the U.S. Patent and Trademark Office has issued a notice of allowance for the company's patent application covering the use of glyceollin to treat diabetes and obesity. MBT is investigating glyceollins for the treatment of metabolic disorders, including diabetes and obesity, as well as their potential role in modulating the gastrointestinal microbiome. Glyceollin I, II and III are small molecule natural products made by soy plants under certain environmental conditions to help combat infectious organisms and other stressors. In animal studies, glyceollins have demonstrated activity in a number of human disease models, including breast and ovarian cancer, hyper-cholesterolemia and metabolic disorders. MBT also announced that it is participating in the One-on-One Partnering sessions of the 17th Annual BIO CEO and Investor Conference in New York City.
Similar Private Companies By Industry
Recent Private Companies Transactions
April 7, 2015
Most Searched Private Companies
Sponsored Financial Commentaries